Ioforminol

DB12439InvestigationalSmall molecule

Ioforminol has been used in trials studying the diagnostic of Cardio Renal Safety in High-risk Elderly Subjects Undergoing a Coronary CATH With or Without PCI.

Formula / weight: C₃₃H₄₀I₆N₆O₁₅ · 1522.137 g/mol (avg)
Code names: Ge 145

Resolves to

Compound

UNII95FNF21CDNCAS1095110-48-7ChEMBLCHEMBL2219417PubChem25222171

Structure

InChIKeyBFVVDRUCXCIALU-UHFFFAOYSA-NSMILESOCC(O)CNC(=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(N(CC(O)CN(C=O)C2=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C2I)C=O)=C1I

What you can answer from here — as of February 21, 2021

2Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Ioforminol, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account